Broadcast Date: 
  • Time: 

As the biologics market continues to grow and the industry focuses on identifying novel targets and mechanisms to generate more effective therapeutics, biological pipelines are evolving from standard antibody formats to next-generation biologics. These advances increase pressure on cell line construction timelines and create challenges in identifying cell lines that meet production needs. As a result, highly optimized cell technologies are required to address these demands.

In this GEN webinar, our distinguished guest, Dr. Peter O’Callaghan, uses the latest in-house data to demonstrate how GS piggyBac® technology addresses these challenges by generating highly productive cell lines. Using a customer case study, Dr. O’Callaghan will outline how implementing the GS piggyBac technology has enabled high expression with reduced clonal variability compared to traditional random integration transfection systems, increasing the efficiency of cell line construction to produce novel IgG-engineered cancer immunotherapies.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Lonza Biologics logo

Peter O’Callaghan
Peter O’Callaghan, PhD
Head of Expression System Sciences